Reading ENTA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ENTA free→Reading ENTA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ENTA free→QuarterlyIQ Insights · ENTA
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 11, 2026, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended March 31, 2026. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed below under Item 5.07, on March 11, 2026, the stockholders of Enanta Pharmaceuticals, Inc. approved an amendment to its 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares. A copy of the amended plan is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On February 9, 2026, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended December 31, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
Results of Operations and Financial Condition. On November 17, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter and year ended September 30, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
Other Events. Public Offering On September 30, 2025, Enanta Pharmaceuticals, Inc. (“Enanta”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale in a public offering of 6,500,000 shares of Enanta’s common stock, par value $0.01 per share (the “Common Stock”). The price to…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 26, 2025, the Board of Directors of Enanta Pharmaceuticals, Inc. (the “Company”) designated Harry R. Trout, III, Vice President, Finance of the Company, as the Company’s interim principal financial officer and Kathleen (“Katie”) S. Capps, CPA, Executive Director, Accounting & Controller, as the Company’s interim principal accounting offic…
Other Events. On August 20, 2025, Enanta announced that it filed suit in the UPC of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the ’265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). This enforcement action targets Pfizer’s activities in the 18 countries of the E…
Results of Operations and Financial Condition. On August 11, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended June 30, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
Results of Operations and Financial Condition. On May 12, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended March 31, 2025. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. As disclosed below under Item 5.07, on March 13, 2025, the stockholders of Enanta Pharmaceuticals, Inc. approved an amendment to its 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 800,000 shares. A copy of the amended plan is filed as Exhibit 10.1 to this Current Report on Form 8-K.
Results of Operations and Financial Condition. On February 10, 2025, Enanta Pharmaceuticals, Inc. announced via press release its results for the fiscal quarter ended December 31, 2024. A copy of Enanta's press release is hereby furnished to the Commission and incorporated by reference herein as Exhibit 99.1.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.